Amoy Diagnostics Co Ltd (SHE:300685) — Market Cap & Net Worth
Market Cap & Net Worth: Amoy Diagnostics Co Ltd (300685)
Amoy Diagnostics Co Ltd (SHE:300685) has a market capitalization of $999.78 Million (CN¥6.83 Billion) as of August 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #8768 globally and #2082 in its home market, demonstrating a 1.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amoy Diagnostics Co Ltd's stock price CN¥17.45 by its total outstanding shares 391536144 (391.54 Million). See Amoy Diagnostics Co Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Amoy Diagnostics Co Ltd Market Cap History: 2017 to 2026
Amoy Diagnostics Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $1.03 Billion to $999.78 Million (17.89% CAGR).
Amoy Diagnostics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amoy Diagnostics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.18x
Amoy Diagnostics Co Ltd's market cap is 1.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.13x
Amoy Diagnostics Co Ltd's market cap is 5.13 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.03 Billion | $330.37 Million | $94.07 Million | 3.12x | 10.97x |
| 2018 | $840.23 Million | $439.03 Million | $126.74 Million | 1.91x | 6.63x |
| 2019 | $1.38 Billion | $578.36 Million | $135.47 Million | 2.38x | 10.17x |
| 2020 | $2.43 Billion | $728.39 Million | $180.33 Million | 3.33x | 13.47x |
| 2021 | $2.35 Billion | $917.03 Million | $239.57 Million | 2.56x | 9.81x |
| 2022 | $1.49 Billion | $842.18 Million | $263.74 Million | 1.78x | 5.67x |
| 2023 | $1.25 Billion | $1.04 Billion | $261.48 Million | 1.20x | 4.78x |
| 2024 | $1.31 Billion | $1.11 Billion | $254.86 Million | 1.18x | 5.13x |
Competitor Companies of 300685 by Market Capitalization
Companies near Amoy Diagnostics Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Amoy Diagnostics Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.77 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #169 globally with a market cap of $137.72 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.48 Billion USD ( CN¥317.64 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #616 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.77 Billion | $574.30 |
| #169 | Danaher Corporation | NYSE:DHR | $137.72 Billion | $194.98 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.48 Billion | CN¥128.43 |
| #616 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $559.07 |
Amoy Diagnostics Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Amoy Diagnostics Co Ltd's market cap moved from $1.03 Billion to $ 999.78 Million, with a yearly change of 17.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥999.78 Million | -14.71% |
| 2025 | CN¥1.17 Billion | -10.26% |
| 2024 | CN¥1.31 Billion | +4.60% |
| 2023 | CN¥1.25 Billion | -16.46% |
| 2022 | CN¥1.49 Billion | -36.40% |
| 2021 | CN¥2.35 Billion | -3.23% |
| 2020 | CN¥2.43 Billion | +76.35% |
| 2019 | CN¥1.38 Billion | +63.92% |
| 2018 | CN¥840.23 Million | -18.60% |
| 2017 | CN¥1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Amoy Diagnostics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $999.78 Million USD |
| MoneyControl | $999.78 Million USD |
| MarketWatch | $999.78 Million USD |
| marketcap.company | $999.78 Million USD |
| Reuters | $999.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more